Posted by Michael Wonder on 01 Nov 2020
MHRA grants HAE patients early access to BioCryst’s berotralstat in United Kingdom
30 October 2020 - BioCryst Pharmaceuticals today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access to Medicines Scheme.
Under the EAMS, hereditary angioedema patients in the UK aged 12 years and older can gain access to berotralstat for the routine prevention of recurrent attacks of hereditary angioedema before the drug is granted marketing authorisation by the European Commission.
